Importantly, enhanced CXCR7 expression was associated with poor prognosis in patients with prostate cancer and glioblastoma, suggesting that CXCR7 may serve as a prognostic biomarker for these two tumors.370, 371. This evidence concerns the gene ACKR3 and glioblastoma.